AbbVie Inc. Available-for-sale Securities, Amortized Cost Basis
AbbVie Inc. (ABBV) had Available-for-sale Securities, Amortized Cost Basis of $1.57 billion as of 2019-06-30, per its 10-Q filed 2019-08-05.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2020-02-21
- 2019-06-30: Available-for-sale Securities, Amortized Cost Basis $1.57B.
- 2019-03-31: Available-for-sale Securities, Amortized Cost Basis $1.61B.
- 2018-12-31: Available-for-sale Securities, Amortized Cost Basis $1.55B.
- 2018-09-30: Available-for-sale Securities, Amortized Cost Basis $1.59B.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2019-06-30 | $1.57B 10-Q · filed 2019-08-05 |
| 2019-03-31 | $1.61B 10-Q · filed 2019-05-03 |
| 2018-12-31 | $1.55B 10-K · filed 2020-02-21 |
| 2018-09-30 | $1.59B 10-Q · filed 2018-11-07 |
| 2018-06-30 | $1.55B 10-Q · filed 2018-08-07 |
| 2018-03-31 | $2.48B 10-Q · filed 2018-05-04 |
| 2017-12-31 | $2.53B 10-K · filed 2019-02-27 |
| 2017-09-30 | $2.49B 10-Q · filed 2017-11-07 |
| 2017-06-30 | $2.54B 10-Q · filed 2017-08-07 |
| 2017-03-31 | $2.51B 10-Q · filed 2017-05-05 |
| 2016-12-31 | $2.00B 10-K · filed 2018-02-16 |
| 2016-09-30 | $1.49B 10-Q · filed 2016-11-07 |
| 2016-06-30 | $1.47B 10-Q · filed 2016-08-05 |
| 2016-03-31 | $1.53B 10-Q · filed 2016-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |